Oxford Biomedica has developed and optimised the analytics required for product commercialisation.
Superior analytics allow us to understand both vector attributes and process performance throughout development and during routine quality control. The challenging analytical methods associated with complex products like lentiviral or AAV vector-based gene therapeutics requires specialist knowledge, techniques, and equipment.
We offer an exceptionally comprehensive suite of in-house assays, ensuring full vector characterisation, quality control and stability testing, and preparing CMC modules for regulatory filings. We have an extensive clinical track record with our own and our partners’ products, and can advise our partners in the selection of appropriate assays. We also develop custom-made assays for specific applications or types of product. Oxford Biomedica is one of the very few companies in the world that can offer in-house, CGMP, RCL (Replication-competent lentiviruses) testing from purpose-built category 3 labs.
Our manufacturing sites are registered with the FDA and we hold manufacturing authorisations for clinical trial products and commercial products.